Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT/QTc Study of OPC-61815 in Healthy Male Subjects
jRCT2080223877Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tolvaptan sodium phosphate (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: QTcF interval change after OPC-61815 dosing. Started Apr 2018; status: completed.
02
Drugs
tolvaptan sodium phosphate
Beyond the preview
Go deeper on jRCT2080223877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223877.